Current and future management of GIST

Clin Adv Hematol Oncol. 2006 Aug;4(8):582-3.
No abstract available

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Benzenesulfonates / adverse effects
  • Benzenesulfonates / therapeutic use
  • Benzoquinones / adverse effects
  • Benzoquinones / therapeutic use
  • Disease Progression
  • Dose-Response Relationship, Drug
  • Gastrointestinal Stromal Tumors / drug therapy*
  • Humans
  • Imatinib Mesylate
  • Indoles / adverse effects
  • Indoles / therapeutic use
  • Lactams, Macrocyclic / adverse effects
  • Lactams, Macrocyclic / therapeutic use
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Piperazines / adverse effects
  • Piperazines / therapeutic use
  • Pyridines / adverse effects
  • Pyridines / therapeutic use
  • Pyrimidines / adverse effects
  • Pyrimidines / therapeutic use
  • Pyrroles / adverse effects
  • Pyrroles / therapeutic use
  • Sorafenib
  • Sunitinib
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzamides
  • Benzenesulfonates
  • Benzoquinones
  • Indoles
  • Lactams, Macrocyclic
  • Phenylurea Compounds
  • Piperazines
  • Pyridines
  • Pyrimidines
  • Pyrroles
  • Niacinamide
  • tanespimycin
  • Imatinib Mesylate
  • Sorafenib
  • nilotinib
  • Sunitinib